In vitro genotoxicity assessment of a novel resveratrol analogue, HS-1793

被引：17

作者：

Jeong M.H. ^{[1
]}

Yang K. ^{[2
]}

Lee C.G. ^{[2
]}

Jeong D.H. ^{[2
]}

Park Y.S. ^{[2
]}

Choi Y.J. ^{[2
]}

Kim J.S. ^{[2
]}

Oh S.J. ^{[2
]}

Jeong S.K. ^{[2
]}

Jo W.S. ^{[2
]}

机构：

[1] Department of Microbiology, Dong-A University College of Medicine, Busan

[2] Department of Research Center, Dong Nam Institute of Radiological and Medical Sciences, Busan

来源：

Toxicological Research | 2014年 / 30卷 / 3期

关键词：

Bacterial mutation assay; Chromosomal aberration assay; Comet assay; Genotoxicity; HS-1793; Resveratrol;

D O I：

10.5487/TR.2014.30.3.211

中图分类号：

学科分类号：

摘要：

Resveratrol has received considerable attention as a polyphenol with various biological effects such as anti-inflammatory, anti-oxidant, anti-mutagenic, anti-carcinogenic, and cardioprotective properties. As part of the overall safety assessment of HS-1793, a novel resveratrol analogue free from the restriction of metabolic instability and the high dose requirement of resveratrol, we assessed genotoxicity in three in vitro assays: a bacterial mutation assay, a comet assay, and a chromosomal aberration assay. In the bacterial reverse mutation assay, HS-1793 did not increase revertant colony numbers in S. typhimurium strains (TA98, TA100, TA1535 and TA1537) or an E. coli strain (WP2 uvrA) regardless of metabolic activation. HS-1793 showed no evidence of genotoxic activity such as DNA damage on L5178Y Tk+/- mouse lymphoma cells with or without the S9 mix in the in vitro comet assay. No statistically significant differences in the incidence of chromosomal aberrations following HS-1793 treatment was observed on Chinese hamster lung cells exposed with or without the S9 mix. These results provide additional evidence that HS-1793 is non-genotoxic at the dose tested in three standard tests and further supports the generally recognized as safe determination of HS-1793 during early drug development.

引用

页码：211 / 220

页数：9

共 35 条

[1]

Gusman J., Malonne H., Atassi G., A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol, Carcinogenesis, 22, pp. 1111-1117, (2001)

[2]

Pervaiz S., Holme A.L., Resveratrol: its biologic targets and functional activity, Antioxid. Redox. Signaling, 11, pp. 2851-2897, (2009)

[3]

Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y., Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies, Anticancer Res., 24, pp. 2783-2840, (2004)

[4]

Park J.W., Choi Y.J., Suh S.I., Baek W.K., Suh M.H., Jin I.N., Min D.S., Woo J.H., Chang J.S., Passaniti A., Lee Y.H., Kwon T.K., Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity, Carcinogenesis, 22, pp. 1633-1639, (2001)

[5]

Saiko P., Szakmary A., Jaeger W., Szekeres T., Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?, Mutat. Res., 658, pp. 68-94, (2008)

[6]

Jeong S.H., Lee J.S., Jeong N.Y., Kim T.H., Yoo K.S., Song S., Suh H., Kwon T.K., Park B.S., Yoo Y.H., A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells, Int. J. Oncol., 35, pp. 1353-1360, (2009)

[7]

Jeong S.H., Jo W.S., Song S., Suh H., Seo S.Y., Lee S.H., Kwon T.K., Yoo Y.H., A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells, Biochem. Pharmacol., 77, pp. 1337-1347, (2009)

[8]

Kim H.J., Yang K.M., Park Y.S., Choi Y.J., Yun J.H., Son C.H., Suh H.S., Jeong M.H., Jo W.S., The novel resveratrol analogue HS-1793 induces apoptosis via the mitochondrial pathway in murine breast cancer cells, Int. J. Oncol., 41, pp. 1628-1634, (2012)

[9]

Jeong S.H., Song I.S., Kim H.K., Lee S.R., Song S., Suh H., Yoon Y.G., Yoo Y.H., Kim N., Rhee B.D., Ko K.S., Han J., An alogue of resveratrol HS-1793 exhibits anticancer activity against MCF-7 Cells via Inhibition of mitochondrial biogenesis bene expression, Mol. Cells, 34, pp. 357-365, (2012)

[10]

Jeong N.Y., Yoon Y.G., Rho J.H., Lee J.S., Lee S.Y., Yoo K.S., Song S., Suh H., Choi Y.H., Yoo Y.H., The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of BclxL, Int. J. Oncol., 38, pp. 1597-1604, (2011)

← 1 2 3 4 →